BioNTech’s $550M acquisition of African AI startup InstaDeep is paying off.
InstaDeep, known for its cutting-edge AI applications, continues to operate independently while boosting BioNTech’s biotech capabilities. In just over a year, the AI company has accelerated BioNTech’s drug and vaccine development, improving processes like tissue analysis by 5x.
Their collaboration now includes breakthrough projects like AI-driven protein design and cancer-fighting innovations. Despite the biotech focus, InstaDeep is still making waves outside pharma, solving industrial challenges like railway scheduling and locust outbreak detection in Africa.
With over 400 employees globally, InstaDeep is thriving under BioNTech’s wing and pushing the frontier of AI innovation across industries.
Read our interview with InstaDeep's CEO Karim Beguir at the link in the bio
Article by Tage Kene-Okafor
Image Credits: InstaDeep; BioNTech
#TechCrunch #technews #artificialintelligence #startup #founder #venturecapital
InstaDeep, known for its cutting-edge AI applications, continues to operate independently while boosting BioNTech’s biotech capabilities. In just over a year, the AI company has accelerated BioNTech’s drug and vaccine development, improving processes like tissue analysis by 5x.
Their collaboration now includes breakthrough projects like AI-driven protein design and cancer-fighting innovations. Despite the biotech focus, InstaDeep is still making waves outside pharma, solving industrial challenges like railway scheduling and locust outbreak detection in Africa.
With over 400 employees globally, InstaDeep is thriving under BioNTech’s wing and pushing the frontier of AI innovation across industries.
Read our interview with InstaDeep's CEO Karim Beguir at the link in the bio
Article by Tage Kene-Okafor
Image Credits: InstaDeep; BioNTech
#TechCrunch #technews #artificialintelligence #startup #founder #venturecapital
BioNTech’s $550M acquisition of African AI startup InstaDeep is paying off.
InstaDeep, known for its cutting-edge AI applications, continues to operate independently while boosting BioNTech’s biotech capabilities. In just over a year, the AI company has accelerated BioNTech’s drug and vaccine development, improving processes like tissue analysis by 5x.
Their collaboration now includes breakthrough projects like AI-driven protein design and cancer-fighting innovations. Despite the biotech focus, InstaDeep is still making waves outside pharma, solving industrial challenges like railway scheduling and locust outbreak detection in Africa.
With over 400 employees globally, InstaDeep is thriving under BioNTech’s wing and pushing the frontier of AI innovation across industries.
Read our interview with InstaDeep's CEO Karim Beguir at the link in the bio 👆
Article by Tage Kene-Okafor
Image Credits: InstaDeep; BioNTech
#TechCrunch #technews #artificialintelligence #startup #founder #venturecapital
·45 Views
·0 voorbeeld